Lactobacillus paracasei (K71 / LP33) for Irritable Bowel Syndrome

Verdict: Published with Warning

Across 6 PubMed studies, the evidence for Lactobacillus paracasei (K71 / LP33) in Irritable Bowel Syndrome grades Tier C — weak evidence. Effective, but with safety or population caveats.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

This claim earns a Weak (C) grade with warning because strain-specific evidence is thin and often null. A 2026 strain-specific meta-analysis (PMID 41682832) evaluated ten probiotic strains for IBS but did not identify L. paracasei among efficacious strains. The CNCM I-1572 pilot (PMID 29881616, n=40) found no significant improvement in IBS symptoms versus placebo.

Positive signals come from mixed-strain or combination trials (PMID 32326347 pairs paracasei with B. longum; PMID 35611667 is a synbiotic with Opuntia) that cannot be attributed to paracasei alone. The genus-level umbrella MA (PMID 37565634, n=8,581) pools heterogeneous strains and overstates strain-specific support.

L11 independently grades this D (needs more evidence) while the published tier is C with warning, reflecting industry-linked marketing of K71/LP33 strains without replicated strain-exact benefit. Do not extrapolate genus-level probiotic meta-analyses to this specific strain.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable

Raw score 0.43

← counter-evidence / ineffectiveeffective / strong evidence →

Final grade

C · Published with Warning

Confidence

76%

Broadly consistent

Evidence level

Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive

L11 AI re-checkIndependent read

0.30

L2 PubMedPrimary literature

0.45

L3 MechanismPlausibility

0.45

L1 ExamineGlobal benchmark

0.50

L5 Clinical bodiesAuthoritative stance

0.50

Against Mixed Supports

▸View the full decision path (audit trail)

compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.43
tier_from_score — 依分數區間映射至 tier letter
apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
tier_strict_requirement_check — Tier 條件達標，未降階
detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (6)L2 · primary research & systematic reviews

Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome

PMID: 2026 統合分析

— See PubMed for details

View on PubMed

Probiotics for the management of irritable bowel syndrome: a systematic review and three-level meta-analysis

PMID: 2023 統合分析 n = 8,581

— See PubMed for details

View on PubMed

Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study

PMID: 32326347 2020 RCT (double-blind) n = 251

Finding: Overall IBS symptom-severity improvement with L. paracasei HA-196 was NOT significantly different from placebo; only subgroup/secondary signals emerged (complete spontaneous bowel movements rose in IBS-C and fell in IBS-D, p=0.013; emotional well-being improved vs baseline).

⚠️ Industry-funded Effect size: Null on primary IBS-SSS; subgroup CSBM change p=0.013

View on PubMed

Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial

PMID: 29881616 2018 RCT (double-blind) n = 40

Finding: L. paracasei CNCM I-1572 did NOT significantly improve the primary clinical endpoints (abdominal pain/discomfort or degree of relief); it only altered surrogate markers (reduced Ruminococcus, increased acetate/butyrate, lowered IL-15).

🟠 Limited quality ⚠️ Industry-funded Effect size: Null on primary clinical endpoints; significant only for surrogate microbiota/immune markers

View on PubMed

Efficacy of a Synbiotic Containing Lactobacillus paracasei DKGF1 and Opuntia humifusa in Elderly Patients with Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial

PMID: 35611667 2023 RCT (double-blind) n = 67

Finding: The L. paracasei DKGF1 + Opuntia humifusa synbiotic gave a significantly higher overall responder rate than placebo (51.5% vs 23.5%, p=0.017), with improved abdominal pain and psychological well-being; note this is a synbiotic, not paracasei monotherapy.

⚠️ Industry-funded Effect size: Responder rate 51.5% vs 23.5%, p=0.017

View on PubMed

Efficacy and Safety of New Lactobacilli Probiotics for Unconstipated Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial

PMID: 31783597 2019 RCT (double-blind) n = 50

Finding: A 3-strain mix containing L. paracasei (with L. salivarius and L. plantarum, 5:4:1) significantly increased SGA responder rate vs placebo (80.8% vs 45.8%, p=0.009; VAS responders 69.2% vs 41.7%, p=0.048), but the paracasei effect cannot be isolated from the co-administered strains.

Government Effect size: SGA responders 80.8% vs 45.8%, p=0.009

View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L5a NIH Office of Dietary Supplements

Cautious

A review of 23 studies (1,919 participants) in which probiotics were tested for treating allergic rhinitis found some evidence that they may be helpful for improving symptoms and quality of life... because the studies tested different probiotics and measured different effects, no recommendations about the use of probiotics could be made. source↗

L5e Specialty Society (condition-mapped)

Cautious

The bugs that seem to help the most are called Bifidobacterium and Lactobacillus. However, not all experts recommend probiotics for IBS because the scientific evidence is limited. source↗

✓PMID 100% verifiedevery citation checked via NCBI Entrez

🔬6 PubMed studiesindependently re-checked by multiple sub-agents

engine_version: v1.0 claim_id: CLM-COND-ibs-INT-lactobacillus-paracasei-001 繁體中文版 →